gsk pre pandemic influenza vaccine

Posted a few hours a go

It seems GSK are focussed on their vaccine instead of Relenza at least they mentioned Relenza in the article.

Cheers


September 2006: GSK reached an agreement with the Simcere
Pharmaceutical Group of Nanjing, China, granting the right to manufacture
and sell the anti-viral influenza treatment zanamivir in China, Indonesia,
Thailand, Vietnam and all Least Developed Countries.
October 18, 2006: GSK signs contracts with Switzerland to supply its
split pre-pandemic antigen and proprietary adjuvant for stockpiling, in
addition to an Advanced Purchase Agreement (APA) for its pandemic vaccine
in the event a pandemic is declared.
November 2006: GSK received a $40 million initial order for bulk
H5N1 antigen from HHS.
-- December 15, 2006: GSK announces that Daronrix(TM) its
alum-adjuvanted whole virus candidate pandemic vaccine; received a positive
opinion from the Committee for Medicinal Products for Human Use.
January 2007: GSK receives from the HHS a $63.3 million contract to
develop antigen-sparing H5N1 pandemic influenza vaccines.
January 2007: GSK begins supplying its antiviral, Relenza(R)
(zanamivir for inhalation), to the U.S. government and begins working with
private-sector businesses and other organizations to provide Relenza(R) as
part of their business continuity planning.
January 4, 2007: GSK entered into an APA with the Danish government
to supply its split candidate pandemic antigen and proprietary adjuvant
once a pandemic has been declared.
January 23, 2007: GSK announced that the file for their proprietary
adjuvanted split antigen pre-pandemic vaccine has been accepted for review
by the CHMP.
Relenza and Daronrix are registered trade marks of the GlaxoSmithKline
group of companies